FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. Disclosed are novel interleukin 10 (IL-10) peptide conjugates, in which a PEG fragment is attached to IL-10 through a dibenzocyclooctine linker using click chemistry. Said conjugate is characterized by an increased half-life in blood plasma and, when dimerized, is able to enhance the effect of tumour-infiltrating immune cells on a set of tumour cells.
EFFECT: invention can be used to modulate T-cell responses in humans, particularly in treating patients suffering from cancer.
36 cl, 7 ex, 10 tbl, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| IL-2 CONJUGATES AND METHODS OF USE THEREOF | 2020 |
|
RU2829327C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
| ESCHERICHIA COLI COMPOSITIONS AND METHODS BASED THEREON | 2021 |
|
RU2821929C1 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| BIOLOGICAL MATERIALS FOR MODULATING IMMUNE RESPONSES | 2017 |
|
RU2770060C2 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| HUMAN INTERLEUKIN-2 VARIANT OR ITS DERIVATIVE | 2019 |
|
RU2799437C2 |
| RECOMBINANT pMHC MOLECULES OF CLASS II | 2017 |
|
RU2777115C2 |
